Human B-Cell Proliferation and Intracellular Signaling: Part 3

Total Page:16

File Type:pdf, Size:1020Kb

Human B-Cell Proliferation and Intracellular Signaling: Part 3 1872 Diabetes Volume 64, June 2015 Andrew F. Stewart,1 Mehboob A. Hussain,2 Adolfo García-Ocaña,1 Rupangi C. Vasavada,1 Anil Bhushan,3 Ernesto Bernal-Mizrachi,4 and Rohit N. Kulkarni5 Human b-Cell Proliferation and Intracellular Signaling: Part 3 Diabetes 2015;64:1872–1885 | DOI: 10.2337/db14-1843 This is the third in a series of Perspectives on intracel- signaling pathways in rodent and human b-cells, with lular signaling pathways coupled to proliferation in pan- a specific focus on the links between b-cell proliferation creatic b-cells. We contrast the large knowledge base in and intracellular signaling pathways (1,2). We highlight rodent b-cells with the more limited human database. what is known in rodent b-cells and compare and contrast With the increasing incidence of type 1 diabetes and that to the current knowledge base in human b-cells. In- the recognition that type 2 diabetes is also due in part variably, the human b-cell section is very brief compared fi b to a de ciency of functioning -cells, there is great ur- with the rodent counterpart, reflecting the still primitive gency to identify therapeutic approaches to expand hu- state of our understanding of mitogenic signaling in hu- b man -cell numbers. Therapeutic approaches might man b-cells. To emphasize this difference, each figure is include stem cell differentiation, transdifferentiation, or divided into two panels, one summarizing rodent b-cell expansion of cadaver islets or residual endogenous signaling and one for human b-cells. Our intended audi- b-cells. In these Perspectives, we focus on b-cell ence includes trainees in b-cell regeneration as well as proliferation. Past Perspectives reviewed fundamental cell cycle regulation and its upstream regulation by experts in a given pathway who wish to refresh their insulin/IGF signaling via phosphatidylinositol-3 kinase/ knowledge regarding other pathways related to b-cell pro- mammalian target of rapamycin signaling, glucose, gly- liferation. We believe that knowledge of b-cell signaling fi cogen synthase kinase-3 and liver kinase B1, protein lags signi cantly behind other areas in b-cell biology, that kinase Cz, calcium-calcineurin–nuclear factor of acti- understanding why adult human b-cells are so recalcitrant vated T cells, epidermal growth factor/platelet-derived to induction of proliferation is critically important, and PERSPECTIVES IN DIABETES growth factor family members, Wnt/b-catenin, leptin, that deepening knowledge in this area will reveal novel and estrogen and progesterone. Here, we emphasize approaches and targets for the therapeutic induction of Janus kinase/signal transducers and activators of tran- human b-cell expansion. scription, Ras/Raf/extracellular signal–related kinase, Readers are urged to refer to the prior two Perspectives for cadherins and integrins, G-protein–coupled receptors, additional background and cross-correlation (1,2). These have and transforming growth factor b signaling. We hope covered the fundamentals of cell cycle control in the b-cell, these three Perspectives will serve to introduce these and several key mitogenic b-cell signaling pathways: insulin/ pathways to new researchers and will encourage addi- IGF/insulin receptor substrate (IRS)/phosphatidylinositol-3 tional investigators to focus on understanding how to kinase (PI3K)/Akt/glycogen synthase kinase-3b (GSK3b)/ harness key intracellular signaling pathways for thera- mammalian target of rapamycin (mTOR) signaling, protein peutic human b-cell regeneration for diabetes. kinase Cz (PKCz) signaling, glucose and nutrient signaling via AMPK/liver kinase B, carbohydrate response element– This is the third in a series of Perspectives in Diabetes binding protein (ChREB) and cMyc, calcium-calcineurin– reviewing and emphasizing the importance of intracellular nuclear factor of activated T cells signaling, epidermal 1Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Corresponding author: Andrew F. Stewart, [email protected], or Rohit Sinai, New York, NY N. Kulkarni, [email protected]. 2 Departments of Medicine and Pediatrics, Johns Hopkins School of Medicine, Received 2 December 2014 and accepted 16 January 2015. Baltimore, MD © 2015 by the American Diabetes Association. Readers may use this article as 3Diabetes Center, University of California, San Francisco, San Francisco, CA long as the work is properly cited, the use is educational and not for profit, and 4Division of Metabolism, Endocrinology & Diabetes, University of Michigan, the work is not altered. Ann Arbor, MI, and VA Ann Arbor Healthcare System, Ann Arbor, MI 5Section of Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA diabetes.diabetesjournals.org Stewart and Associates 1873 growth factor (EGF) and platelet-derived growth factor can activate not only “their own pathway,” but also (PDGF) signaling, Wnt/b-catenin signaling and leptin sig- can cross talk with members of the Ras/Raf/MAPK and naling, estrogen and progesterone signaling, and, a brief PI3K-Akt/protein kinase B (PKB)-mTOR pathways (Fig. introduction to lactogenic signaling. Here, we focus in 1A). This happens via adapter molecules such as Grb2, greater detail on cytokine/Janus kinase/signal trans- Shp2, SHC, SH2B1, IRS2, c-Src, SOS, and others (10– ducers and activators of transcription (JAK-STAT) signal- 15). Thus, a response initiated by a cytokine or hormone ing, Ras/Raf/mitogen-activated protein kinase (MAPK) receptor in the GHR/PRLR family may be driven or en- signaling, cell-cell signaling via cadherins and integrins, hanced by a non–JAK-STAT signaling pathway. Further, G-protein–coupled receptor (GPCR) signaling, and trans- unphosphorylated STATs can also access the nucleus and forming growth factor b (TGFb) superfamily signaling. bind to promoters, in some cases in a competitive manner by inhibiting phospho-STAT DNA binding (3–5). For CYTOKINE AND HORMONE SIGNALING THROUGH unphosphorylated STAT5, tetramers can form and recruit JAK-STAT PATHWAYS Ezh2 (3–5), a component of the polycomb repressive com- Canonical JAK-STAT Signaling plex that regulates, for example, cell cycle inhibitors such b-Cells are exposed to some 60 cytokines (e.g., interleukin as p16INK4. In yet another variation, some STATs can be [IL]-1, IL-2, and IL-6) and hormones (e.g., growth hormone methylated by lysine/histone methylases, such as SET9, [GH], prolactin [PRL], placentallactogens[PLs],leptinand and thereby serve to recruit other transcription complex erythropoietin [EPO]) that signal through JAK-STAT path- members to select promoters (3–5). And in still another ways. Connecting the dimeric or multimeric cell surface example, JAK2 has been reported to link the GHR to the receptors for these molecules to downstream events is a fam- IGF-1 receptor and thereby synergizes to enhance the ily of intracellular signaling molecules that exert positive and effects of GH signaling (16). negative feedback signals to activate signaling and then ter- minate it (reviewed in detail in references [3–9]). Rodent b-Cells In a relevant example of JAK-STAT signaling (Fig. 1A) As reviewed previously (1), PRL/PL have been reported to (3–7,10), under basal conditions, the PRL receptor (PRLR) drive b-cell proliferation in pregnancy via a canonical or GH receptor (GHR) homodimers or heterodimers on the JAK2-STAT5 pathway. This requires the PRLR, as the cell surface are coupled to two JAK2 molecules; cytoplasmic b-cell PRLR knockout (KO) mouse develops b-cell hypo- STAT5 homodimers are loosely bound to the receptor from plasia and gestational diabetes mellitus (17–19). JAK2 is a reservoir in the cytoplasm. GH binding to GHR or PRL to present, and STATs 5a and 5b have been shown to be PRLR rearranges intracellular receptor alignment, activating phosphorylated and to translocate to the nucleus in asso- the JAK2 pair that then cross-phosphorylate one another as ciation with cell cycle activation via cyclin D2, forkhead well as the GHR or PRLR, which then strongly recruits box protein M1 (FoxM1), and other G1/S control mole- STAT5 dimers to the GHR or PRLR. JAK2 then phosphor- cules (20,21). In mice, conditional loss of both STAT5a/b ylates STAT5 homodimers, which causes their disassociation using a pancreatic and duodenal homeobox 1 (Pdx1)-Cre from the GHR or PRLR, permitting STAT5 translocation to (22) or transgenic dominant-negative STAT5 expression the nucleus. Here, phospho-STAT5 homodimers bind (23) results in mild reductions in b-cell proliferation to gamma-interferon–activated sequences (the canonical and function. As also described previously (1), in two STAT response elements) in many promoters, thus initi- parallel cascades, PRLR-JAK2-STAT5 transcriptionally ating transcriptional activation of STAT5 target genes, drives a Bcl6/menin–p18INK4/p27CIP pathway (24), as exemplified by IGF-1 for GH signaling or cell cycle mole- well as serotoninergic pathway via induction of trypto- cules for PRL signaling. phan hydroxylases 1 and 2 (Tph1/2), with induction of proliferation via the serotonin receptor, 5HTR2b (25,26). Terminating JAK-STAT Signaling As a footnote, rodent b-cells contain STAT3, but its con- Activated STATs also trigger suppressors of cytokine ditional loss has no effect on b-cells (27). signaling (SOCS), cytokine-inducible SH2 domain-containing Noncanonical JAK-STAT events occur in b-cells as well. proteins (CISH), and protein inhibitors of activated STAT For example, the cytosolic carboxy-terminal fragment of (PIAS) transcription (Fig. 1A), which act in a classical neg- islet cell antigen 512 (ICA-512-CCF) is released from the ative feedback manner to terminate upstream signals b-cell membrane by insulin secretion and transits to the (8,9). SOCS and CISH accomplish this by competing nucleus, where it enhances STAT5-mediated insulin secre- with JAK-STAT interactions, by blocking the kinase activ- tion and D-cyclin transcription (28). As another nonca- ity of JAK proteins, and by serving as E3 ligase complexes nonical example, the adaptor protein SH2B1, which is that target JAKs and their receptors for ubiquitination known to interact with JAK2, enhances insulin, IGF1, and proteosomal degradation.
Recommended publications
  • Increased Expression of Epidermal Growth Factor Receptor and Betacellulin During the Early Stage of Gastric Ulcer Healing
    505-510 11/6/08 12:55 Page 505 MOLECULAR MEDICINE REPORTS 1: 505-510, 2008 505 Increased expression of epidermal growth factor receptor and betacellulin during the early stage of gastric ulcer healing GEUN HAE CHOI, HO SUNG PARK, KYUNG RYOUL KIM, HA NA CHOI, KYU YUN JANG, MYOUNG JA CHUNG, MYOUNG JAE KANG, DONG GEUN LEE and WOO SUNG MOON Department of Pathology, Institute for Medical Sciences, Chonbuk National University Medical School and the Center for Healthcare Technology Development, Jeonju, Korea Received January 2, 2008; Accepted February 22, 2008 Abstract. Epidermal growth factor receptor (EGFR) is from tissue necrosis triggered by mucosal ischemia, free important for the proliferation and differentiation of gastric radical formation and the cessation of nutrient delivery, which mucosal cells. Betacellulin (BTC) is a novel ligand for EGFR are caused by vascular and microvascular injury such as Since their role is unclear in the ulcer healing process, we thrombi, constriction or other occlusions (2). Tissue necrosis investigated their expression. Gastric ulcers in 30 Sprague- and the release of leukotriene B attract leukocytes and Dawley rats were induced by acetic acid. RT-PCR and macrophages, which release pro-inflammatory cytokines Western blotting were performed to detect EGFR and BTC. (e.g. TNFα, IL-1α, and IL-1ß). These in turn activate local Immunohistochemical studies were performed to detect fibroblasts, endothelial and epithelial cells. Histologically, an EGFR, BTC and proliferating cell nuclear antigen (PCNA). ulcer has two characteristic structures: a distinct ulcer margin The expression of EGFR and the BTC gene was significantly formed by the adjacent non-necrotic mucosa, and granulation increased at 12 h, 24 h and 3 days after ulcer induction tissue composed of fibroblasts, macrophages and proliferating (P<0.05).
    [Show full text]
  • Recombinant Human Betacellulin Promotes the Neogenesis of -Cells
    Recombinant Human Betacellulin Promotes the Neogenesis of ␤-Cells and Ameliorates Glucose Intolerance in Mice With Diabetes Induced by Selective Alloxan Perfusion Koji Yamamoto, Jun-ichiro Miyagawa, Masako Waguri, Reiko Sasada, Koichi Igarashi, Ming Li, Takao Nammo, Makoto Moriwaki, Akihisa Imagawa, Kazuya Yamagata, Hiromu Nakajima, Mitsuyoshi Namba, Yoshihiro Tochino, Toshiaki Hanafusa, and Yuji Matsuzawa Betacellulin (BTC), a member of the epidermal growth factor family, is expressed predominantly in the human pancreas and induces the differentiation of a pancreatic ancreatic ␤-cells are thought to be terminally dif- acinar cell line (AR42J) into insulin-secreting cells, ferentiated cells with little ability to regenerate. suggesting that BTC has a physiologically important However, proliferation of preexisting ␤-cells and role in the endocrine pancreas. In this study, we exam- differentiation of ␤-cells from precursor cells, ined the in vivo effect of recombinant human BTC P (rhBTC) on glucose intolerance and pancreatic mor- mainly residing in the pancreatic duct lining, have been phology using a new mouse model with glucose intoler- demonstrated in some animal models (1–5). Recently, we ance induced by selective alloxan perfusion. RhBTC developed a new mouse model of diabetes induced by selec- (1 µg/g body wt) or saline was injected subcutaneously tive perfusion of alloxan (100 µg/g body wt) during the every day from the day after alloxan treatment. The clamping of the superior mesenteric artery (1). In this model, intraperitoneal glucose tolerance test revealed no dif- glucose intolerance spontaneously resolves after one year ference between rhBTC-treated and rhBTC-untreated because of the proliferation of surviving ␤-cells in the non- glucose-intolerant mice at 2–4 weeks.
    [Show full text]
  • The Crosstalk Between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication
    International Journal of Molecular Sciences Review The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication Janine Wörthmüller * and Curzio Rüegg * Laboratory of Experimental and Translational Oncology, Pathology, Department of Oncology, Microbiology and Immunology (OMI), Faculty of Science and Medicine, University of Fribourg, CH-1700 Fribourg, Switzerland * Correspondence: [email protected] (J.W.); [email protected] (C.R.) Received: 31 October 2020; Accepted: 26 November 2020; Published: 30 November 2020 Abstract: Focal adhesion kinase (FAK) and Wnt signaling pathways are important contributors to tumorigenesis in several cancers. While most results come from studies investigating these pathways individually, there is increasing evidence of a functional crosstalk between both signaling pathways during development and tumor progression. A number of FAK–Wnt interactions are described, suggesting an intricate, context-specific, and cell type-dependent relationship. During development for instance, FAK acts mainly upstream of Wnt signaling; and although in intestinal homeostasis and mucosal regeneration Wnt seems to function upstream of FAK signaling, FAK activates the Wnt/β-catenin signaling pathway during APC-driven intestinal tumorigenesis. In breast, lung, and pancreatic cancers, FAK is reported to modulate the Wnt signaling pathway, while in prostate cancer, FAK is downstream of Wnt. In malignant mesothelioma, FAK and Wnt show an antagonistic relationship: Inhibiting FAK signaling activates the Wnt pathway and vice versa. As the identification of effective Wnt inhibitors to translate in the clinical setting remains an outstanding challenge, further understanding of the functional interaction between Wnt and FAK could reveal new therapeutic opportunities and approaches greatly needed in clinical oncology.
    [Show full text]
  • Serum Protein Fingerprinting by PEA Immunoassay Coupled with a Pattern-Recognition Algorithms Distinguishes MGUS and Multiple Myeloma
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 41), pp: 69408-69421 Research Paper Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma Petra Schneiderova1,*, Tomas Pika2,*, Petr Gajdos3, Regina Fillerova1, Pavel Kromer3, Milos Kudelka3, Jiri Minarik2, Tomas Papajik2, Vlastimil Scudla2 and Eva Kriegova1 1Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic 2Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic 3Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic *These authors have contributed equally to this work Correspondence to: Eva Kriegova, email: [email protected] Keywords: serum pattern, cytokines, growth factors, proximity extension immunoassay, post-transplant serum pattern Received: May 04, 2016 Accepted: July 28, 2016 Published: August 12, 2016 Copyright: Schneiderova et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Serum protein fingerprints associated with MGUS and MM and their changes in MM after autologous stem cell transplantation (MM-ASCT, day 100) remain unexplored. Using highly-sensitive Proximity Extension ImmunoAssay on 92 cancer biomarkers (Proseek Multiplex, Olink), enhanced serum levels of Adrenomedullin (ADM, Pcorr= .0004), Growth differentiation factor 15 (GDF15, Pcorr= .003), and soluble Major histocompatibility complex class I-related chain A (sMICA, Pcorr= .023), all prosurvival and chemoprotective factors for myeloma cells, were detected in MM comparing to MGUS.
    [Show full text]
  • Wnt Signaling in Neuromuscular Junction Development
    Downloaded from http://cshperspectives.cshlp.org/ on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Wnt Signaling in Neuromuscular Junction Development Kate Koles and Vivian Budnik Department of Neurobiology, University of Massachusetts Medical School, Worcester, Massachusetts 01605 Correspondence: [email protected] Wnt proteins are best known for their profound roles in cell patterning, because they are required for the embryonic development of all animal species studied to date. Besides regulating cell fate, Wnt proteins are gaining increasing recognition for their roles in nervous system development and function. New studies indicate that multiple positive and negative Wnt signaling pathways take place simultaneously during the formation of verte- brate and invertebrate neuromuscular junctions. Although some Wnts are essential for the formation of NMJs, others appear to play a more modulatory role as part of multiple signaling pathways. Here we review the most recent findings regarding the function of Wnts at the NMJ from both vertebrate and invertebrate model systems. nt proteins are evolutionarily conserved, though important roles for Wnt signaling have Wsecreted lipo-glycoproteins involved in a become known from studies in both the central wide range of developmental processes in all and peripheral nervous system, this article is metazoan organisms examined to date. In ad- concerned with the role of Wnts at the NMJ. dition to governing many embryonic develop- mental processes, Wnt signaling is also involved WNT LIGANDS, RECEPTORS, AND WNT in nervous system maintenance and function, SIGNALING PATHWAYS and deregulation of Wnt signaling pathways oc- curs in many neurodegenerative and psychiatric Wnts and their receptors comprise a large fam- diseases (De Ferrari and Inestrosa 2000; Carica- ily of proteins.
    [Show full text]
  • Mechanisms of Wnt Signaling in Development
    P1: APR/ary P2: ARS/dat QC: ARS/APM T1: ARS August 29, 1998 9:42 Annual Reviews AR066-03 Annu. Rev. Cell Dev. Biol. 1998. 14:59–88 Copyright c 1998 by Annual Reviews. All rights reserved MECHANISMS OF WNT SIGNALING IN DEVELOPMENT Andreas Wodarz Institut f¨ur Genetik, Universit¨at D¨usseldorf, Universit¨atsstrasse 1, 40225 D¨usseldorf, Germany; e-mail: [email protected] Roel Nusse Howard Hughes Medical Institute and Department of Developmental Biology, Stanford University, Stanford, CA 94305-5428; e-mail: [email protected] KEY WORDS: Wnt, wingless, frizzled, catenin, signal transduction ABSTRACT Wnt genes encode a large family of secreted, cysteine-rich proteins that play key roles as intercellular signaling molecules in development. Genetic studies in Drosophila and Caenorhabditis elegans, ectopic gene expression in Xenopus, and gene knockouts in the mouse have demonstrated the involvement of Wnts in pro- cesses as diverse as segmentation, CNS patterning, and control of asymmetric cell divisions. The transduction of Wnt signals between cells proceeds in a complex series of events including post-translational modification and secretion of Wnts, binding to transmembrane receptors, activation of cytoplasmic effectors, and, finally, transcriptional regulation of target genes. Over the past two years our understanding of Wnt signaling has been substantially improved by the identifi- cation of Frizzled proteins as cell surface receptors for Wnts and by the finding that -catenin, a component downstream of the receptor, can translocate to the nucleus and function as a transcriptional activator. Here we review recent data that have started to unravel the mechanisms of Wnt signaling.
    [Show full text]
  • Mir-449 Overexpression Inhibits Papillary Thyroid Carcinoma Cell Growth by Targeting RET Kinase-Β-Catenin Signaling Pathway
    INTERNATIONAL JOURNAL OF ONCOLOGY 49: 1629-1637, 2016 miR-449 overexpression inhibits papillary thyroid carcinoma cell growth by targeting RET kinase-β-catenin signaling pathway ZONGYU LI1*, XIN HUANG2*, JINKAI XU1, QINGHUA SU1, JUN ZHAO1 and JIANCANG MA1 1Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University; 2Department of General Surgery, The Xi'an Central Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China Received May 20, 2016; Accepted July 13, 2016 DOI: 10.3892/ijo.2016.3659 Abstract. Papillary thyroid carcinoma (PTC) is the most miR-449 overexpression inhibited the growth of PTC by inac- common thyroid cancer and represent approximately 80% of tivating the β-catenin pathway. Thus, miR-449 may serve as a all thyroid cancers. The present study is aimed to investigate potential therapeutic strategy for the treatment of PTC. the role of microRNA (miR)-449 in the progression of PTC. Our results revealed that miR-449 was underexpressed in Introduction the collected PTC specimens compared with non-cancerous PTC tissues. Overexpression of miR-449 induced a cell cycle Thyroid cancer is the leading cause of increased morbidity and arrest at G0/G1 phase and inhibited PTC cell growth in vitro. mortality for endocrine malignancies, and papillary thyroid Further studies revealed that RET proto-oncogene (RET) is carcinoma (PTC) accounts for 80% of thyroid cancer cases (1). a novel miR-449 target, due to miR-449 bound directly to Reports have indicated that PTC have a homogeneous molec- its 3'-untranslated region and miR-449 mimic reduced the ular signature during tumorigenesis compared with other protein expression of RET.
    [Show full text]
  • CIRP Promotes the Progression of Non-Small Cell Lung Cancer Through
    Liao et al. Journal of Experimental & Clinical Cancer Research (2021) 40:275 https://doi.org/10.1186/s13046-021-02080-9 RESEARCH Open Access CIRP promotes the progression of non- small cell lung cancer through activation of Wnt/β-catenin signaling via CTNNB1 Yi Liao1,2†, Jianguo Feng3†, Weichao Sun1, Chao Wu2, Jingyao Li1, Tao Jing4, Yuteng Liang5, Yonghui Qian5, Wenlan Liu1,5* and Haidong Wang2* Abstract Background: Cold-inducible RNA binding protein (CIRP) is a newly discovered proto-oncogene. In this study, we investigated the role of CIRP in the progression of non-small cell lung cancer (NSCLC) using patient tissue samples, cultured cell lines and animal lung cancer models. Methods: Tissue arrays, IHC and HE staining, immunoblotting, and qRT-PCR were used to detect the indicated gene expression; plasmid and siRNA transfections as well as viral infection were used to manipulate gene expression; cell proliferation assay, cell cycle analysis, cell migration and invasion analysis, soft agar colony formation assay, tail intravenous injection and subcutaneous inoculation of animal models were performed to study the role of CIRP in NSCLC cells; Gene expression microarray was used to select the underlying pathways; and RNA immunoprecipitation assay, biotin pull-down assay, immunopurification assay, mRNA decay analyses and luciferase reporter assay were performed to elucidate the mechanisms. The log-rank (Mantel-Cox) test, independent sample T- test, nonparametric Mann-Whitney test, Spearman rank test and two-tailed independent sample T-test were used accordingly in our study. Results: Our data showed that CIRP was highly expressed in NSCLC tissue, and its level was negatively correlated with the prognosis of NSCLC patients.
    [Show full text]
  • The Role of Signaling Pathways in the Development and Treatment of Hepatocellular Carcinoma
    Oncogene (2010) 29, 4989–5005 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The role of signaling pathways in the development and treatment of hepatocellular carcinoma S Whittaker1,2, R Marais3 and AX Zhu4 1Dana-Farber Cancer Institute, Boston, MA, USA; 2The Broad Institute, Cambridge, MA, USA; 3Institute of Cancer Research, London, UK and 4Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA Hepatocellular carcinoma (HCC) is a highly prevalent, malignancy in adults (Pons-Renedo and Llovet, 2003). treatment-resistant malignancy with a multifaceted mole- For the vast majority of patients, HCC is a late cular pathogenesis. Current evidence indicates that during complication of chronic liver disease, and as such, is hepatocarcinogenesis, two main pathogenic mechanisms often associated with cirrhosis. The main risk factors for prevail: (1) cirrhosis associated with hepatic regeneration the development of HCC include infection with hepatitis after tissue damage caused by hepatitis infection, toxins B virus (HBV) or hepatitis C virus (HCV). Hepatitis (for example, alcohol or aflatoxin) or metabolic influ- infection is believed to be the main etiologic factor in ences, and (2) mutations occurring in single or multiple 480% of cases (Anzola, 2004). Other risk factors oncogenes or tumor suppressor genes. Both mechanisms include excessive alcohol consumption, nonalcoholic have been linked with alterations in several important steatohepatitis, autoimmune hepatitis, primary biliary cellular signaling pathways. These pathways are of cirrhosis, exposure to environmental carcinogens (parti- interest from a therapeutic perspective, because targeting cularly aflatoxin B) and the presence of various genetic them may help to reverse, delay or prevent tumorigenesis.
    [Show full text]
  • Beta;-Catenin Signaling in Rhabdomyosarcoma
    Laboratory Investigation (2013) 93, 1090–1099 & 2013 USCAP, Inc All rights reserved 0023-6837/13 Characterization of Wnt/b-catenin signaling in rhabdomyosarcoma Srinivas R Annavarapu1,8,9, Samantha Cialfi2,9, Carlo Dominici2,3, George K Kokai4, Stefania Uccini5, Simona Ceccarelli6, Heather P McDowell2,3,7 and Timothy R Helliwell1 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and accounts for about 5% of all malignant paediatric tumours. b-Catenin, a multifunctional nuclear transcription factor in the canonical Wnt signaling pathway, is active in myogenesis and embryonal somite patterning. Dysregulation of Wnt signaling facilitates tumour invasion and metastasis. This study characterizes Wnt/b-catenin signaling and functional activity in paediatric embryonal and alveolar RMS. Immunohistochemical assessment of paraffin-embedded tissues from 44 RMS showed b-catenin expression in 26 cases with cytoplasmic/membranous expression in 9/14 cases of alveolar RMS, and 15/30 cases of embryonal RMS, whereas nuclear expression was only seen in 2 cases of embryonal RMS. The potential functional significance of b-catenin expression was tested in four RMS cell lines, two derived from embryonal (RD and RD18) RMS and two from alveolar (Rh4 and Rh30) RMS. Western blot analysis demonstrated the expression of Wnt-associated proteins including b-catenin, glycogen synthase kinase-3b, disheveled, axin-1, naked, LRP-6 and cadherins in all cell lines. Cell fractionation and immunofluorescence studies of the cell lines (after stimulation by human recombinant Wnt3a) showed reduced phosphorylation of b-catenin, stabilization of the active cytosolic form and nuclear translocation of b-catenin. Reporter gene assay demonstrated a T-cell factor/lymphoid-enhancing factor-mediated transactivation in these cells.
    [Show full text]
  • Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells
    cancers Article Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells Joachim T. Siaw 1,†, Jonatan L. Gabre 1,2,† , Ezgi Uçkun 1 , Marc Vigny 3, Wancun Zhang 4, Jimmy Van den Eynden 2 , Bengt Hallberg 1 , Ruth H. Palmer 1 and Jikui Guan 1,4,* 1 Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, SE-40530 Gothenburg, Sweden; [email protected] (J.T.S.); [email protected] (J.L.G.); [email protected] (E.U.); [email protected] (B.H.); [email protected] (R.H.P.) 2 Anatomy and Embryology Unit, Department of Human Structure and Repair, Ghent University, 9000 Ghent, Belgium; [email protected] 3 Université Pierre et Marie Curie, UPMC, INSERM UMRS-839, 75005 Paris, France; [email protected] 4 Department of Pediatric Oncology Surgery, Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou 450018, China; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Simple Summary: The anaplastic lymphoma kinase (ALK) and rearranged during transfection (RET) receptor tyrosine kinases (RTKs) are expressed in both the developing neural crest and the pediatric cancer neuroblastoma. Moreover, ALK is mutated in approximately 10% of neuroblastomas. Here, we investigated ALK and RET in neuroblastoma, with the aim of better understanding their respective contributions. Using neuroblastoma cell lines, we show that ALK modulates RET signaling at the level of RET phosphorylation, as well as at the level of transcription. Using CRISPR/Cas9, we generated Citation: Siaw, J.T.; Gabre, J.L.; Uçkun, E.; Vigny, M.; Zhang, W.; Van RET knockout neuroblastoma cell lines and performed a multi-omics approach, combining RNA-Seq den Eynden, J.; Hallberg, B.; Palmer, and proteomics to characterize the effect of deleting RET in a neuroblastoma context.
    [Show full text]
  • Wnt3a Upregulates Brain-Derived Insulin by Increasing Neurod1 Via
    Lee et al. Molecular Brain (2016) 9:24 DOI 10.1186/s13041-016-0207-5 RESEARCH Open Access Wnt3a upregulates brain-derived insulin by increasing NeuroD1 via Wnt/β-catenin signaling in the hypothalamus Jaemeun Lee1, Kyungchan Kim1, Seong-Woon Yu1 and Eun-Kyoung Kim1,2* Abstract Background: Insulin plays diverse roles in the brain. Although insulin produced by pancreatic β-cells that crosses the blood–brain barrier is a major source of brain insulin, recent studies suggest that insulin is also produced locally within the brain. However, the mechanisms underlying the production of brain-derived insulin (BDI) are not yet known. Results: Here, we examined the effect of Wnt3a on BDI production in a hypothalamic cell line and hypothalamic tissue. In N39 hypothalamic cells, Wnt3a treatment significantly increased the expression of the Ins2 gene, which encodes the insulin isoform predominant in the mouse brain, by activating Wnt/β-catenin signaling. The concentration of insulin was higher in culture medium of Wnt3a-treated cells than in that of untreated cells. Interestingly, neurogenic differentiation 1 (NeuroD1), a target of Wnt/β-catenin signaling and one of transcription factors for insulin, was also induced by Wnt3a treatment in a time- and dose-dependent manner. In addition, the treatment of BIO, a GSK3 inhibitor, also increased the expression of Ins2 and NeuroD1. Knockdown of NeuroD1 by lentiviral shRNAs reduced the basal expression of Ins2 and suppressed Wnt3a-induced Ins2 expression. To confirm the Wnt3a-induced increase in Ins2 expression in vivo, Wnt3a was injected into the hypothalamus of mice. Wnt3a increased the expression of NeuroD1 and Ins2 in the hypothalamus in a manner similar to that observed in vitro.
    [Show full text]